News

April 17, 2024

HistoSonics Awarded Prestiguous Edison Innovation Award

Being recognized with an Edison Award™ is one of the highest accolades a company can receive in the name of […]
February 14, 2024

HistoSonics Awarded Key Position in UK’s Novel Innovation Program

Edison Histotripsy System Selected for Competitive Accelerated Market Access Program Minneapolis, MN. February 14th , 2024 – HistoSonics ® , […]
January 9, 2024

World’s First Kidney Tumor Treated Using the HistoSonics’ Edison® Histotripsy System

AdventHealth Celebration (FL.) Urology Performs Non-Invasive Histotripsy in Patient with Primary Solid Renal Tumor   Minneapolis, January 10, 2024 – […]
January 5, 2024

World’s First Patients Treated With Novel Edison® Histotripsy System

MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics, (www.histosonics.com), the manufacturer of the non-invasive Edison® Histotripsy System, announced today a patient from the University of Rochester […]
November 8, 2023

HistoSonics Edison System Recognized with BioTech Breakthrough Award for "MedTech Innovation of the Year"

Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry LOS ANGELES, Nov. 08, 2023 (GLOBE NEWSWIRE) […]
November 6, 2023

HistoSonics Notches Significant Reimbursement Wins

HistoSonics Notches Significant Reimbursement Wins MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics, (www.histosonics.com), the manufacturer of the non-invasive Edison® Histotripsy System and novel sonic beam […]

Last updated on May 30, 2025

Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.

The is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by persons who have completed training performed by HistoSonics Inc., and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions and a summary of clinical trial results, including reported adverse events.

Footer last updated on April 30, 2025
X New Twitter Logo
© 2019-2025 HistoSonics®. All rights reserved.
HistoSonics
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.